Rigel’s current clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in a number of indications. The company has submitted an NDA to the FDA for fostamatinib in patients with chronic or persistent ITP
. The investigation of fostamatinib also includes Phase 2 clinical trials for autoimmune hemolytic anemia (AIHA)
and IgA nephropathy (IgAN)
. In addition, Rigel has product candidates in development with partners BerGenBio AS
, Daiichi Sankyo
, and Aclaris Therapeutics
Recent NewsMore »
|03/06/18||Rigel Announces Fourth Quarter and Year End 2017 Financial Results and Provides Company Update|
|Conference Call and Webcast Today at 5:00 PM Eastern Time
SOUTH SAN FRANCISCO, Calif., March 6, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the fourth quarter and year end 2017.
The U.S. Food and Drug Administration (FDA) is continuing its review of Rigel's New Drug Application (NDA) for fostamatinib for the treatment of adult patients with chronic immune thrombocytopenia (ITP). The Prescription Drug User F... |
|03/01/18||Rigel Announces Two Fostamatinib Presentations at the 4th Biennial Summit of the Thrombosis & Hemostasis Societies of North America|
|SOUTH SAN FRANCISCO, Calif., March 1, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that fostamatinib data from its FIT Phase 3 extension study (FIT3) in patients with chronic immune thrombocytopenia (ITP) and preliminary data from its SOAR Phase 2 clinical study in patients with warm antibody autoimmune hemolytic anemia (AIHA) will be presented at the 4th Biennial Summit of the Thrombosis & Hemostasis Societies of North America on March 8 – 10, 2018 in San... |
|02/27/18||Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2017 Financial Results|
|SOUTH SAN FRANCISCO, Calif., Feb. 27, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2017 financial results after market close on Tuesday, March 6, 2018. Rigel senior management will follow the announcement with a live conference call and webcast at 5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial results and provide a company update.
Participants can access the live conference call by diali... |
Upcoming EventsMore »
There are currently no events scheduled.
|Sign up to receive e-mail alerts whenever Rigel Pharmaceuticals Inc. posts new information to the site. Just enter your e-mail address and click Submit.|